Finance

Lists
Why is CORT down 2.03%?
Dive Deeper
CORT:NASDAQ
Corcept Therapeutics Inc
$116.10
-2.03%
(-2.41) 1D
$116.10
0.00% (0.00)
After hours
Closed: Sep 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CORT...
Open
$119.00
High
$120.44
Low
$114.51
Mkt. cap
12.55B
Avg. vol.
1.42M
Volume
800.80K
P/E ratio
272.50
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
Open
$119.00
High
$120.44
Low
$114.51
Mkt. cap
12.55B
Avg. vol.
1.42M
Volume
800.80K
P/E ratio
272.50
52-wk high
$126.38
52-wk low
$28.66
EPS
$0.43
Beta
0.45
Shares outstanding
108.10M
No. of employees
730
News stories
From web sources and news partners
Profile
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
About Corcept Therapeutics Inc
CEO-
Employees730
FoundedMay 13, 1998
HeadquartersMenlo Park, California, United States
SectorPharmaceutical industry
Websitecorcept.com
Analyst ratings
Based on 5 analysts giving stock ratings to CORT in the past 3 months
Buy
Buy
4
Hold
0
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CORT in the last 3 months.
Highest
Current $116.10
$165.00 (+42.12%)
Average
$141.00 (+21.45%)
Lowest
$50.00 (-56.93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$165.00
+42.1%
09/18/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$165.00
+42.1%
08/21/2026
Srikripa Devarakonda
Truist Financial
Buy
Initiated
$164.00
+41.3%
08/18/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$161.00
+38.7%
08/13/2026
Kalpit Patel
Wolfe Research
Sell
Maintained
$50.00
-56.9%
07/29/2026
Ashwani Verma
UBS
Buy
Upgraded
$72.00
-38%
05/13/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
207.64M
202.12M
164.90M
256.15M
Cost of goods sold
4.60M
2.54M
2.88M
4.06M
Cost of revenue
4.60M
2.54M
2.88M
4.06M
Research and development expenses
68.85M
64.86M
66.26M
53.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
123.98M
130.24M
145.36M
156.90M
Operating expense
192.82M
195.09M
211.62M
210.79M
Total operating expenses
197.42M
197.64M
214.50M
214.85M
Operating income
10.22M
4.49M
-49.60M
41.30M
Other non operating income
-
-
-
-
EBT including unusual items
15.24M
9.91M
-44.72M
45.93M
EBT excluding unusual items
15.24M
9.91M
-44.72M
45.93M
Income tax expense
-4.42M
-14.38M
-12.95M
2.94M
Effective tax rate
-29.03%
-145.09%
28.97%
6.41%
Other operating expenses
-
-
-
-
Net income
19.67M
24.29M
-31.76M
42.99M
Net profit margin
9.47%
12.02%
-19.26%
16.78%
Earnings per share
0.16
0.20
-0.30
0.36
Interest and investment income
5.02M
5.42M
4.89M
4.63M
Interest expense
-
-
-
-
Net interest expenses
5.02M
5.42M
4.89M
4.63M
Depreciation and amortization charges
-
-
-
-
EBITDA
10.51M
4.78M
-49.00M
42.16M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps